by Portfolio Grader | August 30, 2013 1:45 pm
The grades of five Pharmaceutical stocks are better this week, according to the Portfolio Grader[1] database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Alimera Sciences, Inc. (NASDAQ:ALIM[2]) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Alimera Sciences engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. For more information, get Portfolio Grader’s complete analysis of ALIM stock[3].
Johnson & Johnson (NYSE:JNJ[4]) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The stock’s dividend yield is 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock[5].
Bristol-Myers Squibb Company (NYSE:BMY[6]) improves from a C to a B rating this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock[7].
This week, Watson Pharmaceuticals’ (NYSE:WPI[8]) ratings are up from a B last week to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock[9].
This week, Repros Therapeutics (NASDAQ:RPRX[10]) pushes up from a B to an A rating. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock[11].
Louis Navellier’s proprietary Portfolio Grader[12] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[13].
Source URL: https://investorplace.com/2013/08/5-pharmaceutical-stocks-to-buy-now-alim-jnj-bmy-2/
Copyright ©2024 InvestorPlace unless otherwise noted.